Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 074: Empagliflozin Improves Impaired Sensitivity Of Afferent Neurons With Renal Axons

View through CrossRef
Afferent renal nerve pathways likely play a role in salt sensitive hypertension. We recently reported that high salt diet (HS) impairs these afferent renal pathways in rats. Now we tested the hypothesis that during HS a decrease in sensitivity of renal afferent neurons is prevented by the SGLT2 inhibitor empagiflozin.Respective groups of rats were put on HS containing 8% NaCl or a normal diet. Two groups (HS, controls) received empagiflozin 20 mg/kg BW/day orally. Renal neurons were retrogradely labeled with DiI. In culture, labeled dorsal root ganglion neurons (DRG Th11-L2) with renal afferents were investigated electrophysiologically using current clamp mode to assess action potential generation during current injection. Neurons were characterized as tonic highly active (> 5 action potentials, AP) and phasic less active neurons (≤ 5 AP upon stimulation. )In neurons from rats on HS, the relation of tonic highly active neurons to less active phasic neurons shifted consistently towards phasic units (63,8% tonic neurons in controls vs. 42%* on HS, *p<0.05, z-test). However, continuous treatment with empagiflozin preserved the proportion of tonic neurons as in controls (67,9% on HS with concomitant administration of empagiflozin). In controls, empagiflozin did not affect the proportion of tonic to phasic neurons (63,8% tonic neurons in controls vs. 67,9% on HS & empagliflozin, p=0.7, z-test). Blood pressure and heart rate were not altered by HS and/or treatment with any chosen dose of empagiflozin.In rats, chronically elevated sodium intake (8% NaCl) reduced the sensitivity and stimulability of renal afferent DRG neurons. Under these circumstances, concomitant treatment with the SGLT2 inhibitor empagiflozin preserved the function of renal afferent DRG neurons. SGLT 2 inhibitors may help to treat dysfunction of renal innervation in cardiovascular disease.
Title: Abstract 074: Empagliflozin Improves Impaired Sensitivity Of Afferent Neurons With Renal Axons
Description:
Afferent renal nerve pathways likely play a role in salt sensitive hypertension.
We recently reported that high salt diet (HS) impairs these afferent renal pathways in rats.
Now we tested the hypothesis that during HS a decrease in sensitivity of renal afferent neurons is prevented by the SGLT2 inhibitor empagiflozin.
Respective groups of rats were put on HS containing 8% NaCl or a normal diet.
Two groups (HS, controls) received empagiflozin 20 mg/kg BW/day orally.
Renal neurons were retrogradely labeled with DiI.
In culture, labeled dorsal root ganglion neurons (DRG Th11-L2) with renal afferents were investigated electrophysiologically using current clamp mode to assess action potential generation during current injection.
Neurons were characterized as tonic highly active (> 5 action potentials, AP) and phasic less active neurons (≤ 5 AP upon stimulation.
)In neurons from rats on HS, the relation of tonic highly active neurons to less active phasic neurons shifted consistently towards phasic units (63,8% tonic neurons in controls vs.
42%* on HS, *p<0.
05, z-test).
However, continuous treatment with empagiflozin preserved the proportion of tonic neurons as in controls (67,9% on HS with concomitant administration of empagiflozin).
In controls, empagiflozin did not affect the proportion of tonic to phasic neurons (63,8% tonic neurons in controls vs.
67,9% on HS & empagliflozin, p=0.
7, z-test).
Blood pressure and heart rate were not altered by HS and/or treatment with any chosen dose of empagiflozin.
In rats, chronically elevated sodium intake (8% NaCl) reduced the sensitivity and stimulability of renal afferent DRG neurons.
Under these circumstances, concomitant treatment with the SGLT2 inhibitor empagiflozin preserved the function of renal afferent DRG neurons.
SGLT 2 inhibitors may help to treat dysfunction of renal innervation in cardiovascular disease.

Related Results

Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge worldwide and is a pressing public health issue in Pakistan. Patients here often present at ...
Lists, Spatial Practice and Assistive Technologies for the Blind
Lists, Spatial Practice and Assistive Technologies for the Blind
IntroductionSupermarkets are functionally challenging environments for people with vision impairments. A supermarket is likely to house an average of 45,000 products in a median fl...
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure
Background: In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of ...
Empagliflozin preserves mitochondrial function and reduces tubular injury in obese type 2 diabetic ZSF-1 rats
Empagliflozin preserves mitochondrial function and reduces tubular injury in obese type 2 diabetic ZSF-1 rats
Abstract Diabetic nephropathy remains the leading cause of end-stage renal disease. The ZSF-1 rat model combines features known as the metabolic syndrome, such as t...
Effectiveness of SGLT2 inhibitor (Empagliflozin) in reduction of albuminuria in type 2 Diabetics
Effectiveness of SGLT2 inhibitor (Empagliflozin) in reduction of albuminuria in type 2 Diabetics
Introduction: Diabetic kidney dysfunction is a leading cause of end-stage renal disease (ESRD) globally. Empagliflozin is a highly selective inhibitor of sodium-glucose cotransport...

Back to Top